QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:SURF

Surface Oncology Competitors

$9.02
+0.54 (+6.37 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.60
Now: $9.02
$9.14
50-Day Range
$8.44
MA: $11.12
$13.82
52-Week Range
$1.38
Now: $9.02
$14.40
Volume924,653 shs
Average Volume1.27 million shs
Market Capitalization$366.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09

Competitors

Surface Oncology (NASDAQ:SURF) Vs. IMVT, ALEC, ATRA, PCVX, ADVM, and CHRS

Should you be buying SURF stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Surface Oncology, including Immunovant (IMVT), Alector (ALEC), Atara Biotherapeutics (ATRA), Vaxcyte (PCVX), Adverum Biotechnologies (ADVM), and Coherus BioSciences (CHRS).

Surface Oncology (NASDAQ:SURF) and Immunovant (NASDAQ:IMVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares Surface Oncology and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surface OncologyN/A-29.77%-17.05%
ImmunovantN/A-34.80%-32.38%

Analyst Recommendations

This is a summary of recent ratings for Surface Oncology and Immunovant, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surface Oncology02202.50
Immunovant011502.94

Surface Oncology currently has a consensus target price of $12.00, suggesting a potential upside of 33.04%. Immunovant has a consensus target price of $44.4375, suggesting a potential upside of 199.24%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Surface Oncology.

Insider & Institutional Ownership

52.0% of Surface Oncology shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 35.0% of Surface Oncology shares are held by insiders. Comparatively, 0.2% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Surface Oncology and Immunovant's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surface Oncology$15.36 million23.89$-54,790,000.00($1.97)-4.58
ImmunovantN/AN/A$-66,390,000.00($1.54)-9.64

Surface Oncology has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Surface Oncology beats Immunovant on 6 of the 11 factors compared between the two stocks.

Surface Oncology (NASDAQ:SURF) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Profitability

This table compares Surface Oncology and Alector's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surface OncologyN/A-29.77%-17.05%
Alector-757.78%-53.86%-31.44%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Surface Oncology and Alector, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surface Oncology02202.50
Alector00603.00

Surface Oncology presently has a consensus price target of $12.00, indicating a potential upside of 33.04%. Alector has a consensus price target of $33.6667, indicating a potential upside of 93.15%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Surface Oncology.

Earnings & Valuation

This table compares Surface Oncology and Alector's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surface Oncology$15.36 million23.89$-54,790,000.00($1.97)-4.58
Alector$21.22 million65.09$-105,390,000.00($1.71)-10.19

Surface Oncology has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Surface Oncology has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Alector has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. Comparatively, 61.5% of Alector shares are owned by institutional investors. 35.0% of Surface Oncology shares are owned by company insiders. Comparatively, 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alector beats Surface Oncology on 8 of the 14 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Valuation and Earnings

This table compares Atara Biotherapeutics and Surface Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-3.02
Surface Oncology$15.36 million23.89$-54,790,000.00($1.97)-4.58

Surface Oncology has higher revenue and earnings than Atara Biotherapeutics. Surface Oncology is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Atara Biotherapeutics and Surface Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Surface Oncology02202.50

Atara Biotherapeutics currently has a consensus target price of $34.25, suggesting a potential upside of 100.23%. Surface Oncology has a consensus target price of $12.00, suggesting a potential upside of 33.04%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atara Biotherapeutics is more favorable than Surface Oncology.

Profitability

This table compares Atara Biotherapeutics and Surface Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Surface OncologyN/A-29.77%-17.05%

Institutional and Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. 4.3% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 35.0% of Surface Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Atara Biotherapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Summary

Surface Oncology beats Atara Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Insider and Institutional Ownership

74.1% of Vaxcyte shares are held by institutional investors. Comparatively, 52.0% of Surface Oncology shares are held by institutional investors. 35.0% of Surface Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Vaxcyte and Surface Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Surface OncologyN/A-29.77%-17.05%

Earnings & Valuation

This table compares Vaxcyte and Surface Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Surface Oncology$15.36 million23.89$-54,790,000.00($1.97)-4.58

Vaxcyte has higher earnings, but lower revenue than Surface Oncology.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Surface Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Surface Oncology02202.50

Vaxcyte currently has a consensus price target of $48.00, suggesting a potential upside of 85.83%. Surface Oncology has a consensus price target of $12.00, suggesting a potential upside of 33.04%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Vaxcyte is more favorable than Surface Oncology.

Summary

Vaxcyte beats Surface Oncology on 7 of the 9 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Adverum Biotechnologies and Surface Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Surface OncologyN/A-29.77%-17.05%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Adverum Biotechnologies and Surface Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Surface Oncology02202.50

Adverum Biotechnologies currently has a consensus price target of $23.50, indicating a potential upside of 76.43%. Surface Oncology has a consensus price target of $12.00, indicating a potential upside of 33.04%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than Surface Oncology.

Volatility and Risk

Adverum Biotechnologies has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

Insider and Institutional Ownership

97.4% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 52.0% of Surface Oncology shares are owned by institutional investors. 12.4% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 35.0% of Surface Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Adverum Biotechnologies and Surface Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.005,193.63$-64,490,000.00($1.01)-13.19
Surface Oncology$15.36 million23.89$-54,790,000.00($1.97)-4.58

Surface Oncology has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Adverum Biotechnologies beats Surface Oncology on 7 of the 13 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Earnings and Valuation

This table compares Coherus BioSciences and Surface Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million3.24$89.83 million$1.2313.02
Surface Oncology$15.36 million23.89$-54,790,000.00($1.97)-4.58

Coherus BioSciences has higher revenue and earnings than Surface Oncology. Surface Oncology is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Coherus BioSciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by company insiders. Comparatively, 35.0% of Surface Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Coherus BioSciences and Surface Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
Surface OncologyN/A-29.77%-17.05%

Analyst Recommendations

This is a summary of recent recommendations for Coherus BioSciences and Surface Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01502.83
Surface Oncology02202.50

Coherus BioSciences presently has a consensus price target of $27.8571, indicating a potential upside of 73.89%. Surface Oncology has a consensus price target of $12.00, indicating a potential upside of 33.04%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Coherus BioSciences is more favorable than Surface Oncology.

Summary

Coherus BioSciences beats Surface Oncology on 10 of the 14 factors compared between the two stocks.


Surface Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Immunovant logo
IMVT
Immunovant
1.8$14.85+6.3%$1.45 billionN/A-11.51High Trading Volume
Increase in Short Interest
Gap Down
Alector logo
ALEC
Alector
1.3$17.43+4.3%$1.38 billion$21.22 million-7.82Earnings Announcement
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$17.11+1.9%$1.33 billionN/A-3.70News Coverage
Gap Down
PCVX
Vaxcyte
1.8$25.83+8.8%$1.32 billionN/A0.00Upcoming Earnings
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$13.32+3.7%$1.30 billion$250,000.00-10.49
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$16.02+1.4%$1.15 billion$356.07 million7.85Earnings Announcement
Gap Down
Mesoblast logo
MESO
Mesoblast
1.4$9.60+0.0%$1.13 billion$32.16 million-10.91Upcoming Earnings
News Coverage
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.1$29.20+1.6%$1.11 billionN/A0.00
Inhibrx logo
INBX
Inhibrx
1.5$28.89+12.0%$1.09 billionN/A0.00Upcoming Earnings
Cortexyme logo
CRTX
Cortexyme
1.3$36.43+6.5%$1.07 billionN/A-15.18
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$26.87+4.8%$1.01 billionN/A0.00Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.93+0.3%$1.01 billionN/A-4.62Gap Down
Cellectis logo
CLLS
Cellectis
0.8$22.69+5.2%$964.01 million$22.99 million-12.07Upcoming Earnings
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$28.43+6.9%$950.19 millionN/A-11.75Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.18+4.1%$897.91 million$69.89 million-4.58Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.52+7.7%$896.30 millionN/A0.00Upcoming Earnings
News Coverage
Sutro Biopharma logo
STRO
Sutro Biopharma
1.1$23.00+3.5%$887.89 million$42.74 million-255.56Gap Down
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.73+3.3%$886.88 million$1.12 million-5.79Earnings Announcement
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$7.55+5.3%$826.49 million$9.86 million-12.80Earnings Announcement
Gap Down
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$9.88+5.1%$802.08 millionN/A-4.62Earnings Announcement
Analyst Downgrade
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$3.96+1.0%$752.99 million$150.05 million-3.63
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.2$36.79+1.5%$747.57 millionN/A0.00Increase in Short Interest
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$7.40+5.8%$719.75 million$2.51 million-4.48Analyst Report
Increase in Short Interest
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$11.29+2.2%$697.95 millionN/A-1.65Upcoming Earnings
Analyst Revision
News Coverage
Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.2$21.40+3.1%$695.18 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Compugen logo
CGEN
Compugen
1.4$9.97+6.4%$682.15 million$17.80 million-26.95Earnings Announcement
Analyst Revision
Gap Down
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$12.87+7.1%$675.42 million$22.24 million-6.40Gap Down
Curis logo
CRIS
Curis
1.1$10.43+5.7%$613.46 million$10 million-12.72Increase in Short Interest
Gap Down
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.46+2.0%$599.83 million$14.75 million-2.34Upcoming Earnings
News Coverage
MeiraGTx logo
MGTX
MeiraGTx
1.4$15.30+3.0%$587.70 million$13.29 million-10.85
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$14.08+3.6%$531.72 million$4.36 million-4.92Increase in Short Interest
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.25+2.2%$524.68 millionN/A-5.84
HARP
Harpoon Therapeutics
1.5$20.55+6.1%$521.56 million$5.78 million-9.65Gap Down
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.2$13.00+15.5%$518.06 million$147.87 million-4.32Earnings Announcement
Analyst Report
News Coverage
Gap Down
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.52+6.5%$515.03 millionN/A-4.14Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.71+0.3%$488.61 millionN/A0.00Upcoming Earnings
News Coverage
AVROBIO logo
AVRO
AVROBIO
1.7$11.45+3.9%$417.36 millionN/A-3.47Analyst Report
News Coverage
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$18.39+11.9%$403.66 millionN/A0.00Upcoming Earnings
Gap Down
Opthea logo
OPT
Opthea
1.5$9.56+1.2%$403.51 millionN/A0.00Decrease in Short Interest
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
0.8$15.25+2.2%$395.30 millionN/A0.00Analyst Report
High Trading Volume
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75+0.0%$384.69 million$340,000.00-6.98
Cardiff Oncology logo
CRDF
Cardiff Oncology
1.7$10.74+3.7%$379.39 million$250,000.00-3.84Earnings Announcement
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$15.20+1.3%$377.42 millionN/A0.00Increase in Short Interest
Gap Down
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$2.15+0.9%$372.88 million$8.15 million-1.72Decrease in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.04+2.0%$358.91 millionN/A-6.31Decrease in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.86+6.1%$358.44 million$2.91 million-2.39Upcoming Earnings
Increase in Short Interest
Gap Down
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.47+2.7%$353.05 million$96.12 million-13.15Increase in Short Interest
News Coverage
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$10.47+2.9%$340.61 millionN/A-4.31
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.54+3.1%$314.82 million$4.13 million-5.64Gap Down
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.57+2.0%$292.45 millionN/A0.00Upcoming Earnings
Gap Down
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.